4-[2-(1-piperidinyl)ethoxy]phenylmagnesium bromide | 188824-65-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-[2-(1-piperidinyl)ethoxy]phenylmagnesium bromide
• 英文别名: 4-(2-(N-piperidinyl)ethoxy)phenylmagnesium bromide
• CAS: 188824-65-9
• 化学式: C₁₃H₁₈BrMgNO
• 分子量: 308.501
• InChiKey: BKQYDDFUZHWBLD-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  2.19
• 重原子数：
  17.0
• 可旋转键数：
  5.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  12.47
• 氢给体数：
  0.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  4-[2-(1-piperidinyl)ethoxy]phenylmagnesium bromide 在 四丁基氟化铵 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 3.5h， 生成 raloxifene
  参考文献：
  名称：

  Synthesis and Pharmacology of Conformationally Restricted Raloxifene Analogues:  Highly Potent Selective Estrogen Receptor Modulators

  摘要：

  The 2-arylbenzothiophene raloxifene, 1, is a selective estrogen receptor modulator (SERM) which is currently under clinical evaluation for the prevention and treatment of postmenopausal osteoporosis. In vivo structure-activity relationships and molecular modeling studies have indicated that the orientation of the basic amine-containing side chain of 1, relative to the stilbene plane, is an important discriminating factor for the maintenance of tissue selectivity. We have constructed a series of analogues of 1 in which this side chain is held in an orientation which is orthogonal to the stilbene plane, similar to the low-energy conformation predicted for raloxifene. Herein, we report on the synthesis of these compounds and on their activity in a series of in vitro and in vivo biological assays reflective of the SERM profile. In particular, we describe their ability to (I) bind the estrogen receptor, (2) antagonize estrogen-stimulated proliferation of MCF-7 cells in vitro, (3) stimulate TGF-beta 3 gene expression in cell culture, (4) inhibit the uterine effects of ethynyl estradiol in immature rats, and (5) potently reduce serum cholesterol and protect against osteopenia in ovariectomized (OVX) rats without estrogen-like stimulation of uterine tissue. These data demonstrate that one of these compounds, LY357489, 4, is among the most potent SERMs described to date with in vivo efficacy on bone and cholesterol metabolism in OVX rats at doses as low as 0.01 mg/kg/d.

  DOI：

  10.1021/jm970688z
• 作为产物：
  描述：

  1-(2-氯乙基)哌啶盐酸盐 在 potassium carbonate 、 magnesium 作用下， 以 四氢呋喃 、 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 2.84h， 生成 4-[2-(1-piperidinyl)ethoxy]phenylmagnesium bromide
  参考文献：
  名称：

  2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof

  摘要：

  公开号：

  EP1229036B1

文献信息

• Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
  申请人：——

  公开号：US20040259915A1

  公开（公告）日：2004-12-23

  The present invention is directed to novel heteroatom containing tetracyclic derivatives, pharmaceutical compositions containing them, their use in the treatment and/or prevention of disorders mediated by one or more estrogen receptors and processes for their preparation. The compounds of the invention are useful in the treatment and/or prevention of disorders associated with the depletion of estrogen such as hot flashes, vaginal dryness, osteopenia and osteoporosis; hormone sensitive cancers and hyperplasia of the breast, endometrium, cervix and prostate; endometriosis, uterine fibroids, osteoarthritis and as contraceptive agents, alone or in combination with a progestogen or progestogen antagonist.

  本发明涉及新颖的含杂原子四环衍生物、含有它们的药物组合物、它们在治疗和/或预防由一个或多个雌激素受体介导的疾病中的应用，以及它们的制备方法。本发明的化合物在治疗和/或预防与雌激素耗竭相关的疾病中具有用途，例如热潮红、阴道干燥、骨量减少和骨质疏松症；激素敏感性癌症以及乳腺、子宫内膜、宫颈和前列腺的增生；子宫内膜异位症、子宫肌瘤、骨关节炎，以及作为避孕剂，单独使用或与孕激素或孕激素拮抗剂联合使用。
• Intermediates and processes for preparing benzo (b) thiophenes
  申请人：Eli Lilly and Company

  公开号：US06018056A1

  公开（公告）日：2000-01-25

  The instant invention provides processes for preparing compounds of formula IV, V, and IX, having the structures provided hereinbelow: ##STR1## These compounds are useful intermediates in the further preparation of benzo[b] thiophenes.

  本发明提供了制备具有以下结构的化合物IV、V和IX的过程：##STR1## 这些化合物在进一步制备苯并[b]噻吩中起到了重要的中间体作用。
• Novel process and intermediates for preparing 17-halogenated 19-norsteroid compounds
  申请人：Aventis Pharma S.A.

  公开号：US20040224933A1

  公开（公告）日：2004-11-11

  The invention relates to a process for preparing compounds of formula (I): 1 in which R 1 , R 2 , R 3 , n and X are as defined in the description, and to the intermediate compounds for implementing this process.

  该发明涉及制备化合物的过程，其化学式为(I)：其中R1、R2、R3、n和X如描述中所定义，并涉及用于实施该过程的中间化合物。
• 2H-1-benzopyran derivatives processes for their preparation and pharmaceutical compositions thereof
  申请人：——

  公开号：US20040106595A1

  公开（公告）日：2004-06-03

  2H-1-Benzopyran derivatives, processes for their preparation and use thereof for the preparation of pharmaceutical compositions for the prevention and treatment of postmenopausal pathologies.

  2H-1-苯并吡喃衍生物，其制备方法以及将其用于制备预防和治疗绝经后病理的药物组合物的用途。
• [EN] TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS<br/>[FR] HETERO-COMPOSES TETRACYCLIQUES UTILISABLES COMME MODULATEURS DU RECEPTEUR DES OESTROGENES
  申请人：ORTHO MCNEIL PHARM INC

  公开号：WO2003053977A1

  公开（公告）日：2003-07-03

  The present invention is directed to novel heteroatom containing tetracyclic derivatives, pharmaceutical compositions containing them, their use in the treatment and / or prevention of disorders mediated by one or more estrogen receptors and processes for their preparation. The compounds of the invention are useful in the treatment and / or prevention of disorders associated with the depletion of estrogen such as hot flashes, vaginal dryness, osteopenia and osteoporosis; hormone sensitive cancers and hyperplasia of the breast, endometrium, cervix and prostate; endometriosis, uterine fibroids, osteoarthritis and as contraceptive agents, alone or in combination with a progestogen or progestogen antagonist.

  本发明涉及新型含杂原子的四环衍生物、含有它们的药物组合物、它们在治疗和/或预防由一个或多个雌激素受体介导的疾病中的使用以及它们的制备过程。该发明的化合物在治疗和/或预防与雌激素缺乏有关的疾病方面具有用处，例如潮热、阴道干燥、骨质疏松症和骨质疏松症；激素敏感性癌症和乳腺、子宫内膜、子宫颈和前列腺的增生；子宫内膜异位症、子宫肌瘤、骨关节炎以及作为避孕药物，单独使用或与孕激素或孕激素拮抗剂组合使用。